Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( <scp>RACELINES</scp> ): A randomised, double‐blind trial
In T2D people without CKD, the favourable kidney haemodynamic effects of empagliflozin persist in the postprandial state and are irrespective of concurrent use of linagliptin.
Authors
- Michaël J.B. van Baar (ORCID: https://orcid.org/0000-0003-1516-2929)
- Rosalie A. Scholtes (ORCID: https://orcid.org/0000-0002-2794-2263)
- Daan J. Touw (ORCID: https://orcid.org/0000-0002-1429-4789)
- Mark H.H. Kramer (ORCID: https://orcid.org/0000-0001-7996-0466)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Petter Bjornstad (ORCID: https://orcid.org/0000-0002-5160-2947)
- Max Nieuwdorp (ORCID: https://orcid.org/0000-0002-1926-7659)
- Merle M. Krebber (ORCID: https://orcid.org/0000-0001-9856-6907)
- Daniël H. van Raalte (ORCID: https://orcid.org/0000-0003-2894-6124)
- Marcel H.A. Muskiet (ORCID: https://orcid.org/0000-0003-4116-555X)
- Jaap A. Joles
Institutions
- University Health Network (CA)
- University Medical Center Groningen (NL)
- University of Toronto (CA)
- University Medical Center Utrecht (NL)
- Amsterdam University Medical Centers (NL)
- University of Colorado Denver (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1111/dom.16431
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Amsterdam University Medical Centers